PMID- 20831464
OWN - NLM
STAT- MEDLINE
DCOM- 20101104
LR  - 20151119
IS  - 1532-4303 (Electronic)
IS  - 0277-0903 (Linking)
VI  - 47
IP  - 8
DP  - 2010 Oct
TI  - Measured immunoglobulin E in allergic bronchopulmonary aspergillosis treated with 
      omalizumab.
PG  - 942-5
LID - 10.3109/02770903.2010.491144 [doi]
AB  - BACKGROUND: The ability to assess adequate reductions in immunoglobulin E (IgE) 
      in allergic bronchopulmonary aspergillosis (ABPA) has been a concern with regards 
      to omalizumab treatment. OBJECTIVE: To describe the clinical course and serial 
      measured IgE levels in two adult patients with elevated IgE levels, 
      hypersensitivity to Aspergillus fumigatus, and bilateral bronchiectasis who were 
      treated with omalizumab. CLINICAL DESCRIPTIONS: Patient 1 met commonly used 
      criteria for ABPA and had a more than 3-fold increase (from 702 to 2462 IU/ml) in 
      measured IgE 4 months after starting omalizumab. Two years after starting 
      omalizumab, the IgE level decreased to baseline (473 IU/ml) even when 
      corticosteroids were discontinued. Patient 2 had near normalization of elevated 
      IgE levels when treated with corticosteroids but IgE levels subsequently rose 
      again to over 10,000 IU/ml. After reducing the IgE level to 586 IU/ml with higher 
      corticosteroid doses, omalizumab was initiated. Twenty months after starting 
      omalizumab, the measured IgE was 510 IU/ml. Based on published omalizumab 
      treatment-associated total/free IgE ratios, the estimated free IgE levels for 
      both patients after more than a year of omalizumab treatment was less than their 
      pre-omalizumab treatment IgE levels. CONCLUSIONS: These data suggest that 
      omalizumab can be beneficial in treating ABPA and that measured IgE levels can 
      still be useful in this context. Noting the pattern of IgE levels associated with 
      ABPA exacerbations and with corticosteroid treatment may help both with achieving 
      an IgE level appropriate for omalizumab treatment and with the interpretation of 
      measured IgE changes associated with omalizumab treatment.
FAU - Lin, Robert Y
AU  - Lin RY
AD  - Department of Medicine, St Vincent's Hospital-Manhattan-Saint Vincent's Catholic 
      Medical Centers, New York, New York, USA. robert.lin@downtownhospital.org
FAU - Sethi, Sonali
AU  - Sethi S
FAU - Bhargave, Geeta A
AU  - Bhargave GA
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Asthma
JT  - The Journal of asthma : official journal of the Association for the Care of 
      Asthma
JID - 8106454
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Aspergillosis, Allergic Bronchopulmonary/*drug therapy/*immunology
MH  - Aspergillus fumigatus/*immunology
MH  - Bronchiectasis/drug therapy/immunology/microbiology
MH  - Humans
MH  - Immunoglobulin E/blood/*immunology
MH  - Male
MH  - Middle Aged
MH  - Omalizumab
EDAT- 2010/09/14 06:00
MHDA- 2010/11/05 06:00
CRDT- 2010/09/14 06:00
PHST- 2010/09/14 06:00 [entrez]
PHST- 2010/09/14 06:00 [pubmed]
PHST- 2010/11/05 06:00 [medline]
AID - 10.3109/02770903.2010.491144 [doi]
PST - ppublish
SO  - J Asthma. 2010 Oct;47(8):942-5. doi: 10.3109/02770903.2010.491144.